GlobalData suggests the recent approval of new generics in oncology should enhance access and adherence to cancer treatment by reducing costs borne by patients.
The company informs that the drug is priced 96 per cent lower than the innovator brand and reduces the risk of kidney cancer progression by 58 per cent.